|
|
|
|
| Advertisement |
 |
|
|
| Advertisement |
Managing Global Regulatory Complexity: Clinical Trial Transparency, Reporting and Real-time Data Driven Compliance
Wednesday, August 14, 2019 at 12pm EDT | 9am PDT | 5pm BST | 6pm CEST
 Register Now
|
|
|
|
| Global |
 |
|
Ready to Rise in Russia |
Matthias Wernicke, General Manager of Merck KGaA's Biopharma business in Russia, talks about how the country is transitioning from an emerging to a mature pharmaceutical market
… /Read More/ |
| |
|
|
| Special Feature |
 |
|
Pharm Exec's Top 50 Companies 2019 |
Our 19th annual listing reveals some interesting maneuvering of ranks, as companies focus on diversification, big-brand expansions, and positioning a new wave of products to compete in an advancing but complex future treatment market
… /Read More/ |
|
|
|
|
|
| Industry update |
| //G1 Therapeutics (Research Triangle Park, NC) appointed Mark Avagliano as Chief Business Officer.
//
Alkahest (San Carlos, CA) named Robert Klein as Chief Business Officer.
//
NeuBase Therapeutics (Pittsburgh, PA) named Danith Ly, Ph.D. as Chief Scientific Officer.
//
ContraVir Pharmaceuticals (Edison, NJ) announced that its Board of Directors has approved the change of the company's name to Hepion Pharmaceuticals.
//
Harvard Bioscience (Holliston, MA) appointed Michael Rossi as Chief Financial Officer.
//
Ziopharm Oncology (Boston, MA) appointed Satyavrat "Sath" Shukla, CFA, as Chief Financial Officer. Drew Deniger, Ph.D., also joined the company from the National Cancer Institute to lead its program to genetically modify T cells to express neoantigen-specific T-cell receptors.
//
|
|
|
|
|
|
|
|
|
